Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Be6A Lung-01: sigvotatug vedotin versus docetaxel in previously treated nonsquamous non-small cell lung cancer
NL-OMON58805Phase 3Active, not recruiting
- Sponsor
- Seagen Inc.
- Start
- Jun 2024
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of sigvotatug vedotin in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Seagen Inc. Primary endpoint: Overall survival. Started Jun 2024; status: active, not recruiting.
02
Drugs
sigvotatug vedotin
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NL-OMON58805.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON58805.